Head-to-head evidence
Pamlectabart tismanitin vs PHE885
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Pamlectabart tismanitin
Developed by Heidelberg Pharma AG
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2028 · NCT04879043 (registry estimate)
PHE885
Developed by Novartis
NCT04318327 · Phase 1 · terminated
This is an early-phase, open-label study without randomization, blinding, or a control arm, in which every enrolled patient received the CAR-T therapy; its primary goal was to characterize safety and dose-limiting toxicity rather than to compare efficacy against a control treatment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pamlectabart tismanitin's landscape · PHE885's landscape